SCHEMBL21612876

SCHEMBL21612876

CC(C)(C)OC(=O)N1CCCC(OCC(=O)O)C1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51
PRMT5 O14744 2/20 0.49
WDR77 Q9BQA1 2/20 0.49
HPGD P15428 1/20 0.46
USP30 Q70CQ3 3/20 0.42
EPHX1 P07099 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
PDE4B Q07343 1/20 0.41
ACKR3 P25106 1/20 0.41
NR1H2 P55055 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GLS O94925 1/20 0.40
PREP P48147 1/20 0.39
CHEK2 O96017 1/20 0.39
HPGDS O60760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27406223 1.00 MEN1 (0.51) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL4167265 0.92 PRMT5 (0.47) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL21518491 0.92 PRMT5 (0.47) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL4176800 0.92 PRMT5 (0.47) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL27406227 0.86 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL16993101 0.86 MEN1 (0.49) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL5664868 0.86 ALDH1A1 (0.53) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL5664877 0.86 ALDH1A1 (0.53) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL31479863 0.85 PRMT5 (0.49) MEN1ALDH1A1MAPTKMT2APRMT5
SCHEMBL31479168 0.85 PRMT5 (0.49) MEN1ALDH1A1MAPTKMT2APRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112543764-B Amide compound with BET proteolytic induction effect and medical application thereof 田边三菱制药株式会社 2024-05-10 CN disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
CN-111146496-B Polymer electrolyte and lithium ion battery containing same 珠海冠宇电池股份有限公司 2021-07-13 CN disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 EP disclosed
CN-112543764-A Amide compound with BET proteolysis induction effect and medical application thereof 田边三菱制药株式会社 2021-03-23 CN disclosed
CN-111162313-A Polymer electrolyte and lithium ion battery 珠海冠宇电池有限公司 2020-05-15 CN disclosed
CN-111146496-A Polymer electrolyte and lithium ion battery containing same 珠海冠宇电池有限公司 2020-05-12 CN disclosed
WO-2020009176-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF 田辺三菱製薬株式会社 2020-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB MEN1 3119/4885ALDH1A1 4054/4885MAPT 3109/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB MEN1 3245/4885ALDH1A1 4055/4885MAPT 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.